logo
Most depressing jobs revealed in new study

Most depressing jobs revealed in new study

Yahoo4 hours ago

Most jobs come with a paycheque, but some also come at a cost.
A new study suggests that workers in certain industries are significantly more likely to battle depression and frequent mental health issues.
Researchers say that the findings should spark employers to rethink how they design their mental health benefits for employees.
In the study, researchers analyzed survey response data from more than half a million U.S. workers collected between 2015 and 2019.
Of those responses, a whopping 80,319 reported having been diagnosed with depression at some point in their lifetime, the New York Post reported. Women were diagnosed at twice the rate of men.
Industries that stood out as notably grim for workers' mental health included community and social service employees, who reported the highest rates of lifetime diagnosed depression. Food-prep workers and servers trailed close behind.
Workers in the arts, entertainment, sports and media also place high on the list, followed by those in health-care support, education and library services.
At the other end of the equation were workers in mining and construction, who reported the lowest rates of lifetime diagnosed depression.
However, those same industries have the highest rate of suicides among U.S. adult workers, and those numbers have continued to climb since 2000.
Researchers said that the gap might be because both fields are male-dominated, and men might be more likely to seek help for mental health issues.
Dr. Manish Sapra, executive director of Northwell Health's Behavioral Health Service Line, called the study 'significant' and emphasized that certain industries need to have tailored support systems for employees at higher risk of mental health challenges related to their jobs.
'With anything we're doing on well-being or mental health for employees, employers need to customize those benefits and solutions for their specific population and not just pick something off the shelf and give that as a benefit,' he said, per the Post.
Sapra said that health-care workers at Northwell Health often face intense trauma and emotional stress due to witnessing suffering firsthand.
With that in mind, the health system developed specialized support systems, including a peer support network and a stress first aid framework to help employees recognize stress in themselves and others.
Study explores ties between BMI at young age, colorectal cancer
More women digging Mr. Clean look on men, study says
'We've also developed expanded access to mental health services for our employees, which really helps get them help when they need it,' Sapra said. 'We developed some digital technology to do that, basically giving employees access at the touch of a button.'
For other workers, Sapra mentioned the importance of tackling barriers like stigma, cost, and language that might prevent workers from seeking care.
Mental health services must be available when employees can actually use them, he added — for example, offering evening hours for those on daytime shifts.

Hashtags

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Business Wire

time38 minutes ago

  • Business Wire

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Yahoo

time38 minutes ago

  • Yahoo

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Sign in to access your portfolio

Children in most deprived areas more likely to visit A&E and be obese
Children in most deprived areas more likely to visit A&E and be obese

Yahoo

time41 minutes ago

  • Yahoo

Children in most deprived areas more likely to visit A&E and be obese

Children living in England's most deprived areas are more likely to visit A&E, be overweight or obese and suffer from tooth decay, a new report by aid agency Unicef UK has found. The organisation has called on the Government to lift its two-child benefit cap after its findings showed that where children grow up until the age of five has 'a significant impact' on their early outcomes and future potential. In the report published on Monday, every local authority in England was analysed against its level of deprivation and a range of early childhood health and educational outcomes. It found that, when considering early years development, the most deprived authorities were more than twice as far away from achieving the Government's 'good level' target of 75% than the most affluent areas. Only four of the 151 upper tier local authorities in England are currently meeting that target. Nearly twice as many children suffer from late-stage, untreated tooth decay in the most deprived areas (29%) compared to the least deprived (15%), while five-year-old children living in the poorest communities are three times more likely to have had teeth removed due to decay, the report found. Almost a quarter of reception-age children in the most deprived areas (24%) are overweight or obese, while general obesity levels in those areas are more than double those of children in the most affluent areas (12.9%, compared to 6%). There is also an average of 1,020 A&E visits per 1,000 babies and young children in the most deprived areas, an increase of 55% on rates in the most affluent areas, the report found. The five local authorities with the highest levels of deprivation – Blackpool, Knowsley, Liverpool, Kingston upon Hull, and Middlesbrough – were each in the lowest 20% for five of the six child wellbeing measures used in the analysis. Some 1.2 million babies and children under the age of five – 35% of the age group's total population – now live in poverty across England, the report said. It added that child poverty has increased more in the UK then in any of the 38 OECD and EU countries. Among the report's recommendations are long-term, sustainable funding and expanding provision for Family Hubs, recruiting an additional 1,000 health visitors a year and making access to Government-funded childcare hours equal for all children aged two or older, regardless of their location or parental employment. Unicef UK, joined by BBC presenter Dr Chris Van Tulleken, will present a petition calling for investments in early childhood, which has more than 105,000 signatures, to the Prime Minister at 10 Downing Street on Tuesday. Chief executive Dr Philip Goodwin warned the consequences of growing up in poverty can be lifelong and said the report's findings were 'not acceptable'. He said: 'There must be immediate, decisive, and ambitious action by the government. Any further delays will entrench inequality and condemn hundreds of thousands of children to poverty and its effects, as child poverty rates continue to rise. 'The Government must act urgently to lift the two-child limit and the benefit cap and commit to investing in the vital health and education services that support children during their crucial early years.' Introduced in 2015 by then-Conservative chancellor George Osborne, the cap restricts child welfare payments to the first two children born to most families. Sir Keir Starmer said he was 'absolutely determined' to 'drive down' child poverty when he was pressed on the two-child benefit cap in Parliament last week, ahead of the publication of the Government's strategy on the issue.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store